Cart
sales@molnova.com
Sulisobenzone
CAS No. 4065-45-6
Sulisobenzone( —— )
Catalog No. M14401 CAS No. 4065-45-6
Sulisobenzone (benzophenone-4) is an ingredient in some sunscreens which protects the skin from damage by UVB and short-wave UVA ultraviolet light.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 29 | In Stock |
|
Biological Information
-
Product NameSulisobenzone
-
NoteResearch use only, not for human use.
-
Brief DescriptionSulisobenzone (benzophenone-4) is an ingredient in some sunscreens which protects the skin from damage by UVB and short-wave UVA ultraviolet light.
-
DescriptionSulisobenzone (benzophenone-4) is an ingredient in some sunscreens which protects the skin from damage by UVB and short-wave UVA ultraviolet light.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4065-45-6
-
Formula Weight308.31
-
Molecular FormulaC14H12O6S
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESCOC1=C(C=C(C(=O)C2=CC=CC=C2)C(O)=C1)S(O)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nohynek GJ, Schaefer H. Regul Toxicol Pharmacol. 2001 Jun;33(3):285-99.
molnova catalog
related products
-
Decursinol
Decursinol is isolated from the roots of Angelica Gigas with an antinociceptive effect. It also has anti-tumor and anti-metastasis activity.
-
Quercetin 7-O-(6-O-m...
Quercetin 7-O-(6''-O-malonyl)-beta-D-glucoside is a natural product of Justicia, Acanthaceae. Quercetin 7-O-(6''-O-malonyl)-beta-D-glucoside can be used as a reference standard.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
